Scott A. Van Wier

2.8k total citations
20 papers, 1.7k citations indexed

About

Scott A. Van Wier is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Scott A. Van Wier has authored 20 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 12 papers in Molecular Biology and 8 papers in Genetics. Recurrent topics in Scott A. Van Wier's work include Multiple Myeloma Research and Treatments (14 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Protein Degradation and Inhibitors (7 papers). Scott A. Van Wier is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Protein Degradation and Inhibitors (7 papers). Scott A. Van Wier collaborates with scholars based in United States, Spain and Netherlands. Scott A. Van Wier's co-authors include Rafaël Fonseca, Philip R. Greipp, Robert A. Kyle, Richard J. Bailey, Kimberly J. Henderson, Martin M. Oken, Emily Blood, David Harrington, Brian Van Ness and Gordon W. Dewald and has published in prestigious journals such as Blood, British Journal of Haematology and Leukemia.

In The Last Decade

Scott A. Van Wier

20 papers receiving 1.7k citations

Peers

Scott A. Van Wier

HEMAT

ONCOL

GENET

PFM

Gema Mateo Spain

Gösta Gahrton Sweden

B Barlogie United States

Thorsten Graef United States

Scott Van Wier United States

Natalia González-Paz United States

Christine Terré France

P. Leif Bergsagel United States

Laura Chiecchio United Kingdom

Marie‐Christine Kyrtsonis Greece

Gema Mateo Spain

Scott A. Van Wier

1.7k ×1.2

HEMAT

1.2k ×1.1

814 ×1.3

ONCOL

661 ×1.1

GENET

300 ×0.9

PFM

Citations per year, relative to Scott A. Van Wier Scott A. Van Wier (= 1×) peers Gema Mateo

Countries citing papers authored by Scott A. Van Wier

Since Specialization

Citations

This map shows the geographic impact of Scott A. Van Wier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott A. Van Wier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott A. Van Wier more than expected).

Fields of papers citing papers by Scott A. Van Wier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott A. Van Wier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott A. Van Wier. The network helps show where Scott A. Van Wier may publish in the future.

Co-authorship network of co-authors of Scott A. Van Wier

This figure shows the co-authorship network connecting the top 25 collaborators of Scott A. Van Wier. A scholar is included among the top collaborators of Scott A. Van Wier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott A. Van Wier. Scott A. Van Wier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

González‐Calle, Verónica, Niamh Keane, Kathryn E. Pearce, et al.. (2018). Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Annals of Hematology. 97(8). 1453–1462. 24 indexed citations

Colón‐Otero, Gerardo, Scott A. Van Wier, Greg Ahmann, et al.. (2016). Prevalence of BCL-2/J(H) Translocation in Healthy African Americans. Annals of Hematology. 96(1). 51–55. 1 indexed citations

Sebastian, Sinto, Yuan Xiao Zhu, Esteban Braggio, et al.. (2016). Multiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity. Blood. 129(8). 991–1007. 31 indexed citations

Baker, Angela, Esteban Braggio, Susanna Jacobus, et al.. (2013). Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 121(16). 3147–3152. 48 indexed citations

Jacobus, Susanna, Shaji Kumar, Hajime Uno, et al.. (2011). Impact of high‐risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. British Journal of Haematology. 155(3). 340–348. 23 indexed citations

Kumar, Shaji, Hajime Uno, Susanna Jacobus, et al.. (2011). Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 118(16). 4359–4362. 24 indexed citations

Tiedemann, Rodger E., Natalia González-Paz, Robert A. Kyle, et al.. (2008). Genetic aberrations and survival in plasma cell leukemia. Leukemia. 22(5). 1044–1052. 197 indexed citations

Ocio, Enrique M., Roelandt F.J. Schop, Scott A. Van Wier, et al.. (2006). 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. British Journal of Haematology. 136(1). 80–86. 69 indexed citations

Schop, Roelandt F.J., Scott A. Van Wier, Ruifang Xu, et al.. (2006). 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genetics and Cytogenetics. 169(2). 150–153. 55 indexed citations

10.

Fonseca, Rafaël, Scott A. Van Wier, Wee Joo Chng, et al.. (2006). Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 20(11). 2034–2040. 152 indexed citations

11.

Chng, Wee Joo, Rafael Santana-Dávila, Scott A. Van Wier, et al.. (2006). Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 20(5). 807–813. 85 indexed citations

12.

Chng, Wee Joo, Philip R. Greipp, S. M. Jalal, et al.. (2005). Ploidy status rarely changes in myeloma patients at disease progression. Leukemia Research. 30(3). 266–271. 20 indexed citations

13.

Wier, Scott A. Van, Gregory Ahmann, Kimberly J. Henderson, et al.. (2005). The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).. Blood. 106(11). 1545–1545. 6 indexed citations

14.

Gertz, Morie A., Martha Q. Lacy, Angela Dispenzieri, et al.. (2004). Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 (p53) Deletions in Myeloma Patients Treated with High Dose Therapy.. Blood. 104(11). 334–334. 2 indexed citations

15.

Baker, Angela, Tammy Price-Troska, Michael Bittner, et al.. (2004). A Comprehensive Study of Chromosome 13 Abnormalities (Δ 13) in Multiple Myeloma Using High-Throughput, Array-Based Methods.. Blood. 104(11). 1417–1417. 1 indexed citations

16.

Fonseca, Rafaël, Emily Blood, Montserrat Rué, et al.. (2003). Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 101(11). 4569–4575. 448 indexed citations

17.

Fonseca, Rafaël, David Harrington, Martin M. Oken, et al.. (2002). Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.. PubMed. 62(3). 715–20. 139 indexed citations

18.

Schop, Roelandt F.J., Syed M. Jalal, Scott A. Van Wier, et al.. (2002). Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genetics and Cytogenetics. 132(1). 55–60. 39 indexed citations

19.

Schop, Roelandt F.J., W. Michael Kuehl, Scott A. Van Wier, et al.. (2002). Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 100(8). 2996–3001. 124 indexed citations

20.

Fonseca, Rafaël, Emily Blood, Martin M. Oken, et al.. (2002). Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 99(10). 3735–3741. 232 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact